Wednesday, October 7, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Demand Compression Hits Software Layer

Enterprise AI software stocks are in a synchronized collapse: Salesforce down 43% year-to-date, Adobe off 49% year-over-year, Atlassian shedding 4.6%. Accenture has explicitly named 'AI demand compression' in a guidance cut, signaling the enterprise AI services layer is hitting a demand ceiling. IBM, Infosys, and Cognizant face the same headwinds over the next one to two quarters.

LM Salvado
LM Salvado

June 25, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Demand Compression Hits Software Layer
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...
1 The selloff spans the entire enterprise AI software layer simultaneously.

Accenture named the dynamic explicitly. The consulting giant cited "AI demand compression" when cutting its forward guidance — the first major firm to use that phrase directly.1

The pattern points to a ROI credibility problem. Enterprise clients adopted AI tools through 2024 and 2025. Now they are pausing spend pending measurable returns. Vendors who built growth forecasts on AI upsell cycles are repricing.

The damage is concentrated in the software and consulting layer — companies that sell AI to enterprises, not companies that build AI infrastructure. The infrastructure layer, chips and cloud compute, has held relatively firm. The application layer has not.

Three signals define the moment. The declines are clustered: Salesforce, Adobe, and Atlassian are not direct competitors, yet all are falling simultaneously.1 Accenture's guidance language targeted demand, not macro conditions or budget cycles. And the declines have accelerated beyond what sector rotation or interest rate sensitivity explains.

Near-term pressure is expected to persist for one to two quarters as clients wait for clearer ROI evidence before resuming spend.1 IBM, Infosys, and Cognizant — each with material AI consulting revenue — face the same compression dynamic.1

The market is re-rating enterprise AI as a slower-growth category than previously priced. Multiples built on 2024-era adoption projections are contracting. Vendors with diversified legacy revenue streams may absorb the adjustment. Pure-play enterprise AI software faces the harder path.

The core investor question: demand pause or structural ceiling? A pause implies recovery once enterprise clients complete ROI assessments. A ceiling implies the enterprise AI services market is smaller than consensus assumed. The synchronized nature of the current underperformance suggests the ceiling risk is underpriced.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com